Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 10/2014

01-10-2014 | Nephrology – Letter to the Editor

Rituximab in a B cell-driven regimen for the treatment of recurrent membranoproliferative glomerulonephritis after kidney transplantation

Authors: Igor Denizarde Bacelar Marques, Janaina Ramalho, Daísa Ribeiro David, William Carlos Nahas, Elias David-Neto

Published in: International Urology and Nephrology | Issue 10/2014

Login to get access

Excerpt

Editor, …
Literature
1.
Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP et al. (2011) Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol: CJASN 6(7):1609–1616. PubMed PMID: 21700823. Epub 2011/06/28. eng
2.
Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC (2012) Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin Nephrol 77(4):290–295. PubMed PMID: 22445472. Epub 2012/03/27. eng
3.
Perez-Saez MJ, Toledo K, Navarro MD, Lopez-Andreu M, Redondo MD, Ortega R et al. (2011) Recurrent membranoproliferative glomerulonephritis after second renal graft treated with plasmapheresis and rituximab. Transplant Proc 43(10):4005–4009. PubMed PMID: 22172889. Epub 2011/12/17. eng
4.
Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9(1):10–25. PubMed PMID: 19000786. Epub 2008/11/13. eng
5.
Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G (2007) Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol: CJASN 2(5):932–937. PubMed PMID: 17702725. Epub 2007/08/19. eng
Metadata
Title
Rituximab in a B cell-driven regimen for the treatment of recurrent membranoproliferative glomerulonephritis after kidney transplantation
Authors
Igor Denizarde Bacelar Marques
Janaina Ramalho
Daísa Ribeiro David
William Carlos Nahas
Elias David-Neto
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 10/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0792-0

Other articles of this Issue 10/2014

International Urology and Nephrology 10/2014 Go to the issue

Nephrology - Review

Factors that can minimize bleeding complications after renal biopsy

Urology - Original Paper

Acute kidney injury caused by ceftriaxone-induced urolithiasis in children: a single-institutional experience in diagnosis, treatment and follow-up

Nephrology - Original Paper

Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis

Urology - Original Paper

Correlation study of chronic nonbacterial prostatitis with the levels of COX-2 and PGE2 in prostatic secretion

Urology - Original Paper

Ureteroscopic lithotripsy in Trendelenburg position for proximal ureteral calculi: a prospective, randomized, comparative study

Nephrology - Original Paper

Co-administration of Wuzhi capsules and tacrolimus in patients with idiopathic membranous nephropathy: clinical efficacy and pharmacoeconomics
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits